2 weeks Ago By ABMN Staff
Exelixis, Inc. ( NASDAQ:EXEL – Get Free Report ) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 12,690,000 shares, an increase of 5.
5% from the August 31st total of 12,030,000 shares. Based on an average trading volume of 1,770,000 shares, the days-to-cover ratio is currently 7.2 days.
Approximately 4.6% of the shares of the stock are short sold. Insider Transactions at Exelixis In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction dated Monday, September 23rd.
The shares were sold at an average price of $26.38, for a total transaction of $659,500.00.
Following the sale, the executive vice president now directly owns 605,325 shares of the company’s stock, valued at approximately $15,968,473.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink .
In related news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $27.
19, for a total value of $3,398,750.00. Following the transaction, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.
20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link . Also, EVP Jeffrey Hessekiel sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 23rd.
The shares were sold at an average price of $26.38, for a total transaction of $659,500.00.
Following the completion of the transaction, the executive vice president now directly owns 605,325 shares in the company, valued at $15,968,473.50. The disclosure for this sale can be found here .
Insiders have sold a total of 327,858 shares of company stock valued at $8,640,129 in the last ninety days. 2.85% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Exelixis Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LSV Asset Management boosted its position in Exelixis by 1,651.4% in the 1st quarter.
LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock valued at $65,844,000 after buying an additional 2,616,278 shares during the period. Hsbc Holdings PLC boosted its position in Exelixis by 45.3% in the 2nd quarter.
Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock valued at $2,031,000 after buying an additional 28,126 shares during the period. Los Angeles Capital Management LLC boosted its position in Exelixis by 948.3% in the 1st quarter.
Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock valued at $58,240,000 after buying an additional 2,220,150 shares during the period. Farallon Capital Management LLC boosted its position in Exelixis by 1.6% in the 2nd quarter.
Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after buying an additional 424,000 shares during the period. Finally, True Wealth Design LLC purchased a new stake in shares of Exelixis during the 4th quarter worth $828,000. Hedge funds and other institutional investors own 85.
27% of the company’s stock. Analyst Upgrades and Downgrades Read Our Latest Research Report on EXEL Exelixis Stock Performance Shares of NASDAQ EXEL traded up $0.35 during midday trading on Tuesday, reaching $26.
30. 1,297,643 shares of the stock were exchanged, compared to its average volume of 2,024,488. Exelixis has a twelve month low of $18.
64 and a twelve month high of $27.83. The company has a 50 day simple moving average of $25.
63 and a 200 day simple moving average of $23.51. The stock has a market capitalization of $7.
97 billion, a P/E ratio of 40.55, a PEG ratio of 0.56 and a beta of 0.
54. Exelixis ( NASDAQ:EXEL – Get Free Report ) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $0.
75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44.
Exelixis had a net margin of 17.38% and a return on equity of 15.54%.
The firm had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million.
On average, research analysts expect that Exelixis will post 1.59 earnings per share for the current year. Exelixis Company Profile ( Get Free Report ) Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Featured Stories Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter .
.
